Special Issues
Table of Content

Tumor Biomarkers for Diagnosis, Prognosis and Targeted Therapy

Submission Deadline: 31 March 2026 View: 1825 Submit to Special Issue

Guest Editors

Prof. Hung-Yu Lin

Email: linhungyu700218@gmail.com

Affiliation: 1. Department of Post-Baccalaureate Medicine, National Chung Hsing University, Taichung, 402, Taiwan

2. Research Assistant Center, Show Chwan Memorial Hospital, Changhua, 500, Taiwan

Homepage:

Research Interests: Cancer Biology; Biomarker; Metabolism; Mitochondria; Immuno-oncology; Non-coding RNAs; Single-cell Omics; Targeted Therapy; machine learning


Prof. Hsing-Ju Wu

Email: hildawu09@gmail.com

Affiliation: 1. Research Assistant Center, Show Chwan Memorial Hospital, Changhua, 500, Taiwan 2. Department of Nursing, Nursing and Management, Jenteh Junior College of Medicine, Miaoli, 356, Taiwan

Homepage:

Research Interests: Cancer Biology, Molecular Biology, Medical Microbiology


Summary

Tumor biomarkers have become an essential foundation for advancements in cancer diagnosis, prognosis, and targeted therapy. As oncology moves towards precision medicine, significant progress in fields such as immuno-oncology, non-coding RNA research, and the application of pharmacogenetics, and machine learning has provided new opportunities to identify and utilize biomarkers for personalized treatment strategies. These biomarkers play a pivotal role in understanding tumor heterogeneity, predicting therapeutic responses, and assessing disease progression, thereby shaping modern oncology practice.


This Special Issue invites original research articles, comprehensive reviews, and advanced perspectives on the discovery, validation, and clinical implementation of tumor biomarkers. Topics of interest include single-cell omics approaches for tumor ecosystem profiling, biomarker-driven targeted therapy development, and the use of machine learning in biomarker analysis. Additionally, we seek contributions that explore the role of pharmacogenetics in optimizing cancer therapy and the utilization of immune-related biomarkers to enhance therapeutic efficacy in immuno-oncology. By showcasing interdisciplinary contributions, this Special Issue aims to advance biomarker research and provide actionable insights for their integration into clinical oncology, ultimately aiming to improve patient outcomes in the fight against cancer.


Keywords

Cancer Biology; Biomarker; Prognosis; Diagnosis; Therapy; Immuno-oncology; Non-coding RNAs; Single-cell Omics; Pharmacogenetics; Targeted Therapy; Machine Learning

Published Papers


  • Open Access

    REVIEW

    Ferroptosis as a Translational Axis in Small Cell Lung Cancer: A Systematic Review of Redox Pathways and Precision Oncology Prospects

    Donatella Coradduzza, Anna La Salvia, Giuseppe Fanciulli, Maria Rosaria De Miglio
    Oncology Research, DOI:10.32604/or.2025.073045
    (This article belongs to the Special Issue: Tumor Biomarkers for Diagnosis, Prognosis and Targeted Therapy)
    Abstract Background: An increasing number of studies have shown that ferroptosis is related to the initiation and development of small cell lung cancer (SCLC). The systematic review aimed to summarize the characteristics of ferroptosis from its pathogenetic role to translational therapeutic implications in SCLC. Methods: This systematic review, registered in PROSPERO (CRD420251090058), followed PRISMA 2020 guidelines. Comprehensive research of PubMed, Scopus, and Web of Science was performed for studies published between January 2010 and July 2025 investigating ferroptosis mechanisms, genetic or pharmacological modulation, or molecular profiling in SCLC. Two reviewers independently performed data extraction and quality… More >

Share Link